<p>Sarepta Therapeutics, Inc.（纳斯达克代码：SRPT - 获取免费报告）的股票在覆盖该股票的三十家券商中获得了 “持有” 的平均评级，Marketbeat Ratings 报告称。六位股票研究分析师对该股票给予了卖出建议，十五位给予了持有建议，九位对该公司发布了买入建议。在过去一年中，发布报告的券商对该股票的平均 12 个月目标价为 33.68 美元。</p>
<p>获取 <strong>Sarepta Therapeutics</strong> 的提醒：</p>
<ul>
<li>Sarepta 在 2025 年遭遇重创——分析师仍然预测 179% 的上涨空间</li>
</ul>
<p>一些研究分析师对 SRPT 股票发表了看法。美国银行在 10 月 22 日的研究报告中将 Sarepta Therapeutics 的目标价从 16.00 美元上调至 18.00 美元，并给予该股票 “表现不佳” 的评级。Leerink Partners 在 9 月 9 日的研究报告中将 Sarepta Therapeutics 的目标价从 12.00 美元上调至 15.00 美元，并给予该公司 “市场表现” 的评级。富国银行在 11 月 5 日的报告中将 Sarepta Therapeutics 的目标价从 50.00 美元下调至 45.00 美元，并对该公司设定了 “增持” 评级。华尔街 Zen 在 11 月 8 日的报告中将 Sarepta Therapeutics 的评级从 “持有” 下调至 “卖出”。最后，加拿大皇家银行在 10 月 8 日的研究报告中将 Sarepta Therapeutics 的目标价从 14.00 美元上调至 16.00 美元，并给予该公司 “行业表现” 的评级。</p>
<p><strong>获取我们最新的 SRPT 研究报告</strong></p>
<h2>Sarepta Therapeutics 股价上涨 3.5%</h2>
<ul>
<li>Sarepta 因致命事件下跌 42%；市场关注 Solid Biosciences</li>
</ul>
<p>NASDAQ:SRPT 的股票在周三以 22.31 美元开盘。该公司的流动比率为 2.95，速动比率为 1.79，债务与股本比率为 0.78。Sarepta Therapeutics 的 12 个月低点为 10.41 美元，12 个月高点为 129.84 美元。该公司的 50 日移动平均线为 20.88 美元，200 日移动平均线为 20.64 美元。该公司的市值为 23.4 亿美元，市盈率为-7.41，贝塔值为 0.54。</p>
<p>Sarepta Therapeutics（纳斯达克代码：SRPT - 获取免费报告）最近在 11 月 3 日发布了其财报。这家生物技术公司报告本季度每股收益为（0.13 美元），低于市场共识预期的 0.02 美元，差距为（0.15 美元）。Sarepta Therapeutics 的净利润率为-11.25%，股本回报率为-4.85%。该公司本季度的收入为 3.9936 亿美元，而分析师预期为 3.3151 亿美元。去年同期，该公司每股收益为 0.62 美元。Sarepta Therapeutics 本季度的收入较去年同期下降了 14.5%。分析师预计 Sarepta Therapeutics 在当前年度的每股收益为 2.67 美元。</p>
<h2>对 Sarepta Therapeutics 的对冲基金看法</h2>
<ul>
<li>制药行业抛售：RSI 显示你不应忽视的 3 只股票</li>
</ul>
<p>一些大型投资者最近增加或减少了对 SRPT 的持股。Ancora Advisors LLC 在第一季度将其在 Sarepta Therapeutics 的持股增加了 150.0%。Ancora Advisors LLC 现在拥有 500 股该生物技术公司的股票，价值 32,000 美元，此前在该期间内又购买了 300 股。Brooklyn Investment Group 在第一季度将其在 Sarepta Therapeutics 的持股增加了 450.4%。Brooklyn Investment Group 现在拥有 721 股该生物技术公司的股票，价值 46,000 美元，此前在上个季度又购买了 590 股。Banque Transatlantique SA 在第一季度购买了 Sarepta Therapeutics 的新头寸，价值约 44,000 美元。iSAM Funds UK Ltd 在第三季度获得了 Sarepta Therapeutics 的新股份，价值约 25,000 美元。最后，Byrne Asset Management LLC 在第三季度购买了 Sarepta Therapeutics 的新头寸，价值约 33,000 美元。目前 86.68% 的股票由机构投资者和对冲基金持有。</p>
<h2>Sarepta Therapeutics 公司简介</h2>
<p>（获取免费报告）</p>
<p>Sarepta Therapeutics, Inc.是一家商业阶段的生物制药公司，专注于 RNA 靶向治疗、基因治疗和其他基因治疗方式的发现与开发，以治疗罕见疾病。它提供 EXONDYS 51 注射剂，用于治疗具有可跳过外显子 51 突变的杜氏肌营养不良症（duchenne）患者；VYONDYS 53 用于治疗具有可跳过外显子 53 突变的杜氏肌营养不良症患者；AMONDYS 45 用于治疗具有突变的杜氏肌营养不良症患者；以及 ELEVIDYS，一种基于腺病毒相关病毒的基因治疗，用于治疗 4 至 5 岁有杜氏肌营养不良症突变的步态儿童患者。</p>
<h2>另见</h2>
<ul>
<li>我们更看好的五只股票，而不是 Sarepta Therapeutics</li>
<li>什么是空头头寸？如何使用它</li>
<li>为什么台湾半导体的 6.5% 下跌可能是一个明智的买入</li>
<li>成长股：它们是什么，它们又不是些什么</li>
<li>RTX 因国防订单激增而飙升至历史新高</li>
<li>投资者如何识别并成功交易缺口下跌的股票</li>
<li>聪明的钱正在购买汽车供应商，而不是汽车品牌</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9U1JQVA?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9U1JQVA"/></p>
<p><em>此即时新闻提醒由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或意见发送至 contact@marketbeat.com。</em></p>
<h2>你现在应该投资 1,000 美元在 Sarepta Therapeutics 吗？</h2>
<p>在你考虑 Sarepta Therapeutics 之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已经识别出五只顶级分析师正在悄悄建议客户现在购买的股票，以便在更广泛的市场注意到之前……而 Sarepta Therapeutics 并不在名单上。</p>
<p>虽然 Sarepta Therapeutics 目前在分析师中被评为持有评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

Sarepta医疗

<p>Sarepta Therapeutics, Inc.（纳斯达克代码：SRPT）获得了 30 家券商的平均 “持有” 评级。分析师的意见不一：6 家建议卖出，15 家建议持有，9 家建议买入。12 个月的平均目标价为 33.68 美元。最近的分析师行动包括美国银行、Leerink Partners、富国银行和加拿大皇家银行的目标价调整。该股票开盘价为 22.31 美元，市值为 23.4 亿美元。机构投资者持有 86.68% 的股份。Sarepta 专注于针对罕见疾病的 RNA 靶向治疗</p>

<p>Shares of Sarepta Therapeutics, Inc. (NASDAQ:SRPT - Get Free Report) have earned an average rating of &#34;Hold&#34; from the thirty brokerages that are covering the stock, Marketbeat Ratings reports. Six equities research analysts have rated the stock with a sell recommendation, fifteen have given a hold recommendation and nine have issued a buy recommendation on the company. The average 12 month price target among brokerages that have issued a report on the stock in the last year is $33.68.</p>
<div class="lb-trans"><p>Sarepta Therapeutics, Inc.（纳斯达克代码：SRPT - 获取免费报告）的股票在覆盖该股票的三十家券商中获得了 “持有” 的平均评级，Marketbeat Ratings 报告称。六位股票研究分析师对该股票给予了卖出建议，十五位给予了持有建议，九位对该公司发布了买入建议。在过去一年中，发布报告的券商对该股票的平均 12 个月目标价为 33.68 美元。</p>
</div><p>Get <strong>Sarepta Therapeutics</strong> alerts:</p>
<div class="lb-trans"><p>获取 <strong>Sarepta Therapeutics</strong> 的提醒：</p>
</div><ul>
<li>Brutal 2025 for Sarepta—Analysts Still Call for 179% Upside</li>
</ul>
<div class="lb-trans"><ul>
<li>Sarepta 在 2025 年遭遇重创——分析师仍然预测 179% 的上涨空间</li>
</ul>
</div><p>A number of research analysts have weighed in on SRPT shares. Bank of America upped their price objective on shares of Sarepta Therapeutics from $16.00 to $18.00 and gave the stock an &#34;underperform&#34; rating in a research report on Wednesday, October 22nd. Leerink Partners lifted their price target on Sarepta Therapeutics from $12.00 to $15.00 and gave the company a &#34;market perform&#34; rating in a research note on Tuesday, September 9th. Wells Fargo &amp; Company reduced their price target on Sarepta Therapeutics from $50.00 to $45.00 and set an &#34;overweight&#34; rating for the company in a report on Wednesday, November 5th. Wall Street Zen lowered Sarepta Therapeutics from a &#34;hold&#34; rating to a &#34;sell&#34; rating in a report on Saturday, November 8th. Finally, Royal Bank Of Canada boosted their price objective on Sarepta Therapeutics from $14.00 to $16.00 and gave the company a &#34;sector perform&#34; rating in a research report on Wednesday, October 8th.</p>
<div class="lb-trans"><p>一些研究分析师对 SRPT 股票发表了看法。美国银行在 10 月 22 日的研究报告中将 Sarepta Therapeutics 的目标价从 16.00 美元上调至 18.00 美元，并给予该股票 “表现不佳” 的评级。Leerink Partners 在 9 月 9 日的研究报告中将 Sarepta Therapeutics 的目标价从 12.00 美元上调至 15.00 美元，并给予该公司 “市场表现” 的评级。富国银行在 11 月 5 日的报告中将 Sarepta Therapeutics 的目标价从 50.00 美元下调至 45.00 美元，并对该公司设定了 “增持” 评级。华尔街 Zen 在 11 月 8 日的报告中将 Sarepta Therapeutics 的评级从 “持有” 下调至 “卖出”。最后，加拿大皇家银行在 10 月 8 日的研究报告中将 Sarepta Therapeutics 的目标价从 14.00 美元上调至 16.00 美元，并给予该公司 “行业表现” 的评级。</p>
</div><p><strong>Get Our Latest Research Report on SRPT</strong></p>
<div class="lb-trans"><p><strong>获取我们最新的 SRPT 研究报告</strong></p>
</div><h2>Sarepta Therapeutics Trading Up 3.5%</h2>
<div class="lb-trans"><h2>Sarepta Therapeutics 股价上涨 3.5%</h2>
</div><ul>
<li>Sarepta Drops 42% on Fatalities; Markets Eye Solid Biosciences</li>
</ul>
<div class="lb-trans"><ul>
<li>Sarepta 因致命事件下跌 42%；市场关注 Solid Biosciences</li>
</ul>
</div><p>Shares of NASDAQ:SRPT opened at $22.31 on Wednesday. The company has a current ratio of 2.95, a quick ratio of 1.79 and a debt-to-equity ratio of 0.78. Sarepta Therapeutics has a 12-month low of $10.41 and a 12-month high of $129.84. The business has a 50 day moving average of $20.88 and a two-hundred day moving average of $20.64. The company has a market capitalization of $2.34 billion, a PE ratio of -7.41 and a beta of 0.54.</p>
<div class="lb-trans"><p>NASDAQ:SRPT 的股票在周三以 22.31 美元开盘。该公司的流动比率为 2.95，速动比率为 1.79，债务与股本比率为 0.78。Sarepta Therapeutics 的 12 个月低点为 10.41 美元，12 个月高点为 129.84 美元。该公司的 50 日移动平均线为 20.88 美元，200 日移动平均线为 20.64 美元。该公司的市值为 23.4 亿美元，市盈率为-7.41，贝塔值为 0.54。</p>
</div><p>Sarepta Therapeutics (NASDAQ:SRPT - Get Free Report) last posted its earnings results on Monday, November 3rd. The biotechnology company reported ($0.13) earnings per share for the quarter, missing the consensus estimate of $0.02 by ($0.15). Sarepta Therapeutics had a negative net margin of 11.25% and a negative return on equity of 4.85%. The firm had revenue of $399.36 million for the quarter, compared to analysts' expectations of $331.51 million. During the same period last year, the firm earned $0.62 earnings per share. Sarepta Therapeutics's revenue for the quarter was down 14.5% compared to the same quarter last year. As a group, analysts forecast that Sarepta Therapeutics will post 2.67 EPS for the current year.</p>
<div class="lb-trans"><p>Sarepta Therapeutics（纳斯达克代码：SRPT - 获取免费报告）最近在 11 月 3 日发布了其财报。这家生物技术公司报告本季度每股收益为（0.13 美元），低于市场共识预期的 0.02 美元，差距为（0.15 美元）。Sarepta Therapeutics 的净利润率为-11.25%，股本回报率为-4.85%。该公司本季度的收入为 3.9936 亿美元，而分析师预期为 3.3151 亿美元。去年同期，该公司每股收益为 0.62 美元。Sarepta Therapeutics 本季度的收入较去年同期下降了 14.5%。分析师预计 Sarepta Therapeutics 在当前年度的每股收益为 2.67 美元。</p>
</div><h2>Hedge Funds Weigh In On Sarepta Therapeutics</h2>
<div class="lb-trans"><h2>对 Sarepta Therapeutics 的对冲基金看法</h2>
</div><ul>
<li>Pharma Fire Sale: 3 Stocks the RSI Says You Shouldn’t Ignore</li>
</ul>
<div class="lb-trans"><ul>
<li>制药行业抛售：RSI 显示你不应忽视的 3 只股票</li>
</ul>
</div><p>A number of large investors have recently added to or reduced their stakes in SRPT. Ancora Advisors LLC grew its position in shares of Sarepta Therapeutics by 150.0% in the first quarter. Ancora Advisors LLC now owns 500 shares of the biotechnology company's stock valued at $32,000 after purchasing an additional 300 shares during the period. Brooklyn Investment Group raised its position in shares of Sarepta Therapeutics by 450.4% in the first quarter. Brooklyn Investment Group now owns 721 shares of the biotechnology company's stock valued at $46,000 after buying an additional 590 shares during the last quarter. Banque Transatlantique SA purchased a new position in Sarepta Therapeutics in the 1st quarter worth approximately $44,000. iSAM Funds UK Ltd acquired a new stake in shares of Sarepta Therapeutics in the third quarter valued at approximately $25,000. Finally, Byrne Asset Management LLC purchased a new position in Sarepta Therapeutics during the third quarter worth approximately $33,000. 86.68% of the stock is currently owned by institutional investors and hedge funds.</p>
<div class="lb-trans"><p>一些大型投资者最近增加或减少了对 SRPT 的持股。Ancora Advisors LLC 在第一季度将其在 Sarepta Therapeutics 的持股增加了 150.0%。Ancora Advisors LLC 现在拥有 500 股该生物技术公司的股票，价值 32,000 美元，此前在该期间内又购买了 300 股。Brooklyn Investment Group 在第一季度将其在 Sarepta Therapeutics 的持股增加了 450.4%。Brooklyn Investment Group 现在拥有 721 股该生物技术公司的股票，价值 46,000 美元，此前在上个季度又购买了 590 股。Banque Transatlantique SA 在第一季度购买了 Sarepta Therapeutics 的新头寸，价值约 44,000 美元。iSAM Funds UK Ltd 在第三季度获得了 Sarepta Therapeutics 的新股份，价值约 25,000 美元。最后，Byrne Asset Management LLC 在第三季度购买了 Sarepta Therapeutics 的新头寸，价值约 33,000 美元。目前 86.68% 的股票由机构投资者和对冲基金持有。</p>
</div><h2>Sarepta Therapeutics Company Profile</h2>
<div class="lb-trans"><h2>Sarepta Therapeutics 公司简介</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（获取免费报告）</p>
</div><p>Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.</p>
<div class="lb-trans"><p>Sarepta Therapeutics, Inc.是一家商业阶段的生物制药公司，专注于 RNA 靶向治疗、基因治疗和其他基因治疗方式的发现与开发，以治疗罕见疾病。它提供 EXONDYS 51 注射剂，用于治疗具有可跳过外显子 51 突变的杜氏肌营养不良症（duchenne）患者；VYONDYS 53 用于治疗具有可跳过外显子 53 突变的杜氏肌营养不良症患者；AMONDYS 45 用于治疗具有突变的杜氏肌营养不良症患者；以及 ELEVIDYS，一种基于腺病毒相关病毒的基因治疗，用于治疗 4 至 5 岁有杜氏肌营养不良症突变的步态儿童患者。</p>
</div><h2>See Also</h2>
<div class="lb-trans"><h2>另见</h2>
</div><ul>
<li>Five stocks we like better than Sarepta Therapeutics</li>
<li>What is Short Interest? How to Use It</li>
<li>Why Taiwan Semiconductor's 6.5% Dip Could Be a Smart Buy</li>
<li>Growth Stocks: What They Are, What They Are Not</li>
<li>RTX Surges to Record Highs as Defense Orders Explode</li>
<li>How Investors Can Identify and Successfully Trade Gap-Down Stocks</li>
<li>Smart Money Is Buying Auto Suppliers, Not Car Brands</li>
</ul>
<div class="lb-trans"><ul>
<li>我们更看好的五只股票，而不是 Sarepta Therapeutics</li>
<li>什么是空头头寸？如何使用它</li>
<li>为什么台湾半导体的 6.5% 下跌可能是一个明智的买入</li>
<li>成长股：它们是什么，它们又不是些什么</li>
<li>RTX 因国防订单激增而飙升至历史新高</li>
<li>投资者如何识别并成功交易缺口下跌的股票</li>
<li>聪明的钱正在购买汽车供应商，而不是汽车品牌</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9U1JQVA" alt="" original-src="https://www.marketbeat.com/scripts/RatingsChart.ashx?Prefix=NASDAQ&amp;Symbol=SRPT"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或意见发送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Sarepta Therapeutics Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1,000 美元在 Sarepta Therapeutics 吗？</h2>
</div><p>Before you consider Sarepta Therapeutics, you'll want to hear this.</p>
<div class="lb-trans"><p>在你考虑 Sarepta Therapeutics 之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Sarepta Therapeutics wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已经识别出五只顶级分析师正在悄悄建议客户现在购买的股票，以便在更广泛的市场注意到之前……而 Sarepta Therapeutics 并不在名单上。</p>
</div><p>While Sarepta Therapeutics currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 Sarepta Therapeutics 目前在分析师中被评为持有评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

Sarepta Therapeutics, Inc. (NASDAQ:SRPT) 被券商给予平均 “持有” 建议